Overview
What it is.
GHRP-2 is a growth hormone secretagogue from an earlier generation of GHRPs. It reliably stimulates GH release in research models, and is also studied for its comparatively larger effect on cortisol and prolactin relative to newer, more selective secretagogues.
Research Areas
- Studied for its potential role in growth hormone secretion
- Studied for its potential role in appetite-related research
- Studied in comparison with more selective growth hormone secretagogues
Batch & Testing
Proof, not promises.
COA ships with every order
Every batch we release is independently HPLC tested before it ever reaches a lab bench. Browse the full certificate library.
Research Deep-Dive
How it works.
Research Deep-Dive
How it works.
GHRP-2 (pralmorelin) is an early-generation growth hormone secretagogue and the only compound of its kind to ever receive approval from a national drug regulator anywhere in the world — Japan's PMDA approved it in 2004, but strictly as a diagnostic test for growth hormone deficiency, not as a standing therapy.
GHRP-2 activates the ghrelin receptor (GHS-R1a), triggering GH release from the pituitary. Compared with newer, more selective secretagogues, GHRP-2 also meaningfully raises ACTH, cortisol, and prolactin, which is the tradeoff researchers point to when comparing it against options like ipamorelin.
Use Cases Explored
- Studied for its potential role in growth hormone secretion, including as a diagnostic stimulation test
- Studied for its potential role in appetite stimulation
- Studied in comparison with more selective growth hormone secretagogues for its cortisol and prolactin effects
The Evidence
Approved as a diagnostic agent in Japan (2004)
Japan's PMDA approved pralmorelin as a diagnostic test for GH deficiency based on a multicenter randomized trial (N=120) validating a GH-response cutoff, plus an earlier validation study (N=85) — real regulatory approval, but for a one-time diagnostic injection, not ongoing use.
Failed Phase II therapeutic trials for short stature
A separate development track studying GHRP-2 as a growth-promoting therapy for GH-deficient children — including an intranasal formulation — increased endogenous GH secretion but did not translate into clinically significant height gains over 24 weeks, and that program was discontinued.
No FDA approval or U.S. trial program
GHRP-2 has never been approved by the FDA for any use and has no active U.S. clinical trials as of this writing; its only regulatory approval anywhere is Japan's narrow diagnostic indication.
Specifications
The essentials.
Specifications
The essentials.
- Vial Capacity
- 3 ml glass vial
- Form
- Lyophilized powder
- Solubility
- Reconstitute with bacteriostatic water
- Storage
- Store in a cool, dry place. Refrigerate at 2–8°C after reconstitution
- Shelf Life
- 24 months lyophilized; 4–6 weeks refrigerated after reconstitution
Growth Hormone
GHRP-2
Pralmorelin
An earlier-generation growth-hormone-releasing peptide studied for GH stimulation.
Size
COA-backed guarantee — independently test any vial; if it's under 99% purity, full refund + testing costs covered.
All products sold by One Tap Peptides are intended for laboratory research use only. Not for human consumption. Not intended for animal use. Not intended for diagnostic or therapeutic purposes.
Related
